Companies: 10,795·Total market cap: $144.5T
IDEAYA Biosciences, Inc.

IDEAYA Biosciences, Inc.

IDYANASDAQHealthcare● Active
$31.48
+$3.19(+11.28%)
Market Cap$2.8B
P/E Ratio
52W High$39.28
52W Low$20.455
Overview

IDEAYA Biosciences, Inc. (IDYA) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

idya · pe ratio · data through Dec 31, 2025

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for IDEAYA Biosciences, Inc. (IDYA) measures how much investors pay for each dollar of the company's trailing earnings. IDYA's current PE ratio of N/A is calculated by dividing its stock price of $31.48 by its TTM earnings per share of -$1.58.

N/A
P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31

Forward P/E
N/A
FY2027 est. EPS $-3.79
Based on 12 analysts
EPS (TTM)
-$1.58
TTM · diluted EPS
PEG Ratio
-0.45
Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · IDEAYA Biosciences, Inc. SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-08

PE Ratio History

2017 – 2025 · Annual
PE Ratio (TTM)
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Biotechnology · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
IDEAYA Biosciences, Inc.
IDEAYA Biosciences, Inc.You
IDYA
$2.8BN/A-$1.58
Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation
ADPT
$2.7BN/A-$0.39
Beam Therapeutics Inc.
Beam Therapeutics Inc.
BEAM
$3.1BN/A-$0.81
Cidara Therapeutics, Inc.
Cidara Therapeutics, Inc.
CDTX
$5.6BN/A-$26.75
Cogent Biosciences, Inc.
Cogent Biosciences, Inc.
COGT
$5.3BN/A-$4.87
Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc.
FOLD
$4.5BN/A-$0.09
Kiniksa Pharmaceuticals, Ltd.
Kiniksa Pharmaceuticals, Ltd.
KNSA
$3.7B51.87x$0.80

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 9 of 9 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2025-12-31Latest
FY2025
$-1.28
2024-12-31
FY2024
$-3.36
2023-12-31
FY2023
$-1.96
2022-12-31
FY2022
$-1.42
2021-12-31
FY2021
$-1.41
2020-12-31
FY2020
$-1.40
2019-12-31
FY2019
$-2.07
2018-12-31
FY2018
$-2.41
2017-12-31
FY2017
$-0.83

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for IDEAYA Biosciences, Inc. (IDYA) measures how much investors pay for each dollar of the company's trailing earnings. IDYA's current PE ratio of N/A is calculated by dividing its stock price of $31.48 by its TTM earnings per share of -$1.58.

PE Ratio = Stock Price ÷ EPS (TTM)
= $31.48 ÷ -$1.58 = N/A
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Frequently asked questions

IDYA pe ratio · 6 questions

IDYA's current PE ratio is N/A as of 2026-06-08, based on a stock price of $31.48 and TTM EPS of -$1.58. Data sourced from Financial Modeling Prep via IDYA's SEC 10-K and 10-Q filings.

IDYA PE ratioWhat is IDYA PE ratioCurrent PE ratio of IDYAIDYA PE ratio today

Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · IDEAYA Biosciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08